
Project GRF 007 IGF-I (ng/ml) serum concentrations following repeated injections of GRF's analogs (hGRF(1-29) NH2)

TABLE 1

T. C.						
ireatment (ΒΙD, 20 μg/kg SC)	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6
					•	
Saline	216 ±33	241 ± 33	251 ± 31	262 + 43	264 + 31	244 + 37
(hexanoyl),hGRF(1-29)NH2	27 + 16	252 100	8 00 a	8 00 . 000	10 1 10 1 10 1 1 1 1 1 1 1 1 1 1 1 1 1	
	77 7 10	771 CC7	300 I 30	377 ± 78	300 エ 30 322 エ 28 334 エ 29 11 309 ± 29	1309 ± 29
(heyenow] trans 3) toneye						
MICACHOY I CIAIIS-2/onGRF (1-29) NH2	$^{-29)}$ NH ₂ 197 ± 20	225 ± 16	271 ± 16 ª	319 ± 22 a.b	319 ± 22 a,b 325 + 29 a,b 294 + 21 a,b	294 + 21 A.b
(hexenoyl trans-3),hGRF(1-29)NH2	-29) NH ₂ 222 ± 22	299 ± 30 ª	357 + 43 8	373 + 36 a,b	373 + 36 8,b 344 + 00 8 270 , 00 8,b	270 - 20 a.b
			2 4	00 T 010	34 I I 72	95 H 076
-						

a = P < 0.05 when compared to day 1
b = P < 0.05 when compared to day 2
Day 1 = Pretreatment
Treatment P=0.18
Days P< 0.0001
Treatment x Days P < 0.0001



Effect of repeated SC injection (20 μg/kg BID x 4 days) of GRF analogs on serum IGF-1 levels

TABLE 2

Treatment (BID, 20 μg/kg, SC)	Day 1 Pretreatment	Day 2	Day 3	Day 4	Day 5
	ng/ml	ng/ml	ng/ml	ng/ml	ng/ml
hGRF(1-29)NH2	252 ± 28	235 ± 19	263 ± 16	258 ± 17	262 ± 24
(Octanoyl) hGRF(1-29)NH2	316 ± 22	.287 ± 20	301 ±37	301 ± 37	318 ± 39
(Hexanoyl)₀ hGRF(1-29)NH₂	248 ± 20	281 ± 28	299 ± 26	319 ± 22ª	342 ± 21 a,b
(Butyryl) hGRF(1-29)NH2	278 ± 20	281 ± 24	302 ± 26	289 ± 26	293 ± 23

Treatment P= 0.42 Day P = 0.0004 Treatment x Day P= 0.011 a = P < 0.05 when compared to day 1 b = P < 0.05 when compared to day2